Pharmaceutical Research

, Volume 28, Issue 8, pp 1819–1830

Intratumoral Drug Delivery with Nanoparticulate Carriers

Expert Review

ABSTRACT

Stiff extracellular matrix, elevated interstitial fluid pressure, and the affinity for the tumor cells in the peripheral region of a solid tumor mass have long been recognized as significant barriers to diffusion of small-molecular-weight drugs and antibodies. However, their impacts on nanoparticle-based drug delivery have begun to receive due attention only recently. This article reviews biological features of many solid tumors that influence transport of drugs and nanoparticles and properties of nanoparticles relevant to their intratumoral transport, studied in various tumor models. We also discuss several experimental approaches employed to date for enhancement of intratumoral nanoparticle penetration. The impact of nanoparticle distribution on the effectiveness of chemotherapy remains to be investigated and should be considered in the design of new nanoparticulate drug carriers.

KEY WORDS

extracellular matrix intratumoral distribution interstitial fluid pressure nanoparticles solid tumors 

REFERENCES

  1. 1.
    Jang SH, Wientjes MG, Lu D, Au JLS. Drug delivery and transport to solid tumors. Pharm Res. 2003;20(9):1337–50.PubMedGoogle Scholar
  2. 2.
    Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–64.PubMedGoogle Scholar
  3. 3.
    Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–92.PubMedGoogle Scholar
  4. 4.
    Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8(3):241–54.PubMedGoogle Scholar
  5. 5.
    Young JS, Lumsden CE, Stalker AL. The significance of the “tissue pressure” of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol. 1950;62(3):313–33.PubMedGoogle Scholar
  6. 6.
    Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1–3):149–68.PubMedGoogle Scholar
  7. 7.
    Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvas Res. 1989;37(1):77–104.Google Scholar
  8. 8.
    Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48(24 Pt 1):7022–32.PubMedGoogle Scholar
  9. 9.
    Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145–7.PubMedGoogle Scholar
  10. 10.
    Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990;50(15):4478–84.PubMedGoogle Scholar
  11. 11.
    Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - An obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806–13.PubMedGoogle Scholar
  12. 12.
    Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6(8):583–92.PubMedGoogle Scholar
  13. 13.
    Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JLS. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290(2):871–80.PubMedGoogle Scholar
  14. 14.
    Lankelma J, Dekker H, Luque RF, Luykx S, Hoekman K, van der Valk P, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999;5(7):1703–7.PubMedGoogle Scholar
  15. 15.
    Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–82.PubMedGoogle Scholar
  16. 16.
    Fleming JM, Miller TC, Quinones M, Xiao Z, Xu X, Meyer MJ, et al. The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med. 2010;8:27.PubMedGoogle Scholar
  17. 17.
    Park K. A new ligand for targeted drug delivery to tumor stromal cells. J Control Release. 2010;145(2):75.PubMedGoogle Scholar
  18. 18.
    Reed RK, Rubin K. Transcapillary exchange: role and importance of the interstitial fluid pressure and the extracellular matrix. Cardiovasc Res. 2010;87(2):211–7.PubMedGoogle Scholar
  19. 19.
    Ushiki T. Collagen fibers, reticular fibers and elastic fibers. A comprehensive understanding from a morphological viewpoint. Arch Histol Cytol. 2002;65(2):109–26.PubMedGoogle Scholar
  20. 20.
    Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003;200(4):448–64.PubMedGoogle Scholar
  21. 21.
    Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer. 2010;46(7):1181–8.PubMedGoogle Scholar
  22. 22.
    Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609–52.PubMedGoogle Scholar
  23. 23.
    Koninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, et al. Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun. 2004;322(3):943–9.PubMedGoogle Scholar
  24. 24.
    Comalada M, Cardo M, Xaus J, Valledor AF, Lloberas J, Ventura F, et al. Decorin reverses the repressive effect of autocrine-produced TGF-beta on mouse macrophage activation. J Immunol. 2003;170(9):4450–6.PubMedGoogle Scholar
  25. 25.
    Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, et al. Sustained down-regulation of the epidermal growth factor receptor by decorin - A mechanism for controlling tumor growth in vivo. J Biol Chem. 2000;275(42):32879–87.PubMedGoogle Scholar
  26. 26.
    Schonherr E, Levkau B, Schaefer L, Kresse H, Walsh K. Decorin-mediated signal transduction in endothelial cells - Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). J Biol Chem. 2001;276(44):40687–92.PubMedGoogle Scholar
  27. 27.
    Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature. 1990;346(6281):281–4.PubMedGoogle Scholar
  28. 28.
    Theocharis AD, Vynios DH, Papageorgakopoulou N, Skandalisa SS, Theocharis DA. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol. 2003;35(3):376–90.PubMedGoogle Scholar
  29. 29.
    Reed CC, Gauldie J, Iozzo RV. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene. 2002;21(23):3688–95.PubMedGoogle Scholar
  30. 30.
    Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA. 1995;92(15):7016–20.PubMedGoogle Scholar
  31. 31.
    Teicher BA, Maehara Y, Kakeji Y, Ara G, Keyes SR, Wong J, et al. Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin. Int J Cancer. 1997;71(1):49–58.PubMedGoogle Scholar
  32. 32.
    Tsara ME, Theocharis AD, Theocharis DA. Compositional and structural alterations of proteoglycans in human rectum carcinoma with special reference to versican and decorin. Anticancer Res. 2002;22(5):2893–8.PubMedGoogle Scholar
  33. 33.
    Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891–906.PubMedGoogle Scholar
  34. 34.
    Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer. 2009;9(2):108–22.PubMedGoogle Scholar
  35. 35.
    Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol. 2001;189(3):266–74.PubMedGoogle Scholar
  36. 36.
    Park CC, Rembert J, Chew K, Moore D, Kerlikowske K. High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2009;73(1):75–9.PubMedGoogle Scholar
  37. 37.
    Kolacna L, Bakesova J, Varga F, Kostakova E, Planka L, Necas A, et al. Biochemical and biophysical aspects of collagen nanostructure in the extracellular matrix. Physiol Res. 2007;56 Suppl 1:S51–60.PubMedGoogle Scholar
  38. 38.
    Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49–54.PubMedGoogle Scholar
  39. 39.
    Feng YM, Sun BC, Li XQ, Zhang L, Niu Y, Xiao CH, et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat. 2007;103(3):319–29.PubMedGoogle Scholar
  40. 40.
    Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008;27(40):5373–84.PubMedGoogle Scholar
  41. 41.
    Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60(9):2497–503.PubMedGoogle Scholar
  42. 42.
    Pfeiffer BJ, Franklin CL, Hsieh FH, Bank RA, Phillips CL. Alpha 2(I) collagen deficient oim mice have altered biomechanical integrity, collagen content, and collagen crosslinking of their thoracic aorta. Matrix Biol. 2005;24(7):451–8.PubMedGoogle Scholar
  43. 43.
    Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metastasis. 2009;26(1):35–49.PubMedGoogle Scholar
  44. 44.
    Postovit LM, Abbott DE, Payne SL, Wheaton WW, Margaryan NV, Sullivan R, et al. Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration. J Cell Biochem. 2008;103(5):1369–78.PubMedGoogle Scholar
  45. 45.
    Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, et al. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer. 2010;126(11):2653–62.PubMedGoogle Scholar
  46. 46.
    Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.PubMedGoogle Scholar
  47. 47.
    Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001;155(3):459–70.PubMedGoogle Scholar
  48. 48.
    Zhao HB, Ross FP, Teitelbaum SL. Unoccupied alpha(v)beta(3) integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol Endocrinol. 2005;19(3):771–80.PubMedGoogle Scholar
  49. 49.
    Sawada Y, Tamada M, Dubin-Thaler BJ, Cherniavskaya O, Sakai R, Tanaka S, et al. Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell. 2006;127(5):1015–26.PubMedGoogle Scholar
  50. 50.
    Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol. 2002;4(4):E83–90.PubMedGoogle Scholar
  51. 51.
    Han SW, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006;66(1):315–23.PubMedGoogle Scholar
  52. 52.
    Vellon L, Menendez JA, Lupu R. alpha(v)beta(3) integrin regulates Heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene. 2005;24(23):3759–73.PubMedGoogle Scholar
  53. 53.
    Bohme U, Scheler U. Effective charge of bovine serum albumin determined by electrophoresis NMR. Chem Phys Lett. 2007;435:342–5.Google Scholar
  54. 54.
    Lohle PNM, Verhagen I, Teelken AW, Blaauw EH, Go KG. The pathogenesis of cerebral gliomatous cysts. Neurosurgery. 1992;30(2):180–5.PubMedGoogle Scholar
  55. 55.
    Ding Y, Bian X, Yao W, Li R, Ding D, Hu Y, et al. Surface-potential-regulated transmembrane and cytotoxicity of chitosan/gold hybrid nanospheres. ACS Appl Mater Interfaces. 2010;2(5):1456–65.PubMedGoogle Scholar
  56. 56.
    Asadishad B, Vosoughi M, Alamzadeh I, Tavakoli A. Synthesis of folate-modified, polyethylene glycol-functionalized gold nanoparticles for targeted drug delivery. J Dispers Sci Technol. 2010;31(4):492–500.Google Scholar
  57. 57.
    Cho WS, Cho M, Jeong J, Choi M, Han BS, Shin HS, et al. Size-dependent tissue kinetics of PEG-coated gold nanoparticles. Toxicol Appl Pharmacol. 2010;245(1):116–23.PubMedGoogle Scholar
  58. 58.
    Pornpattananangkul D, Olson S, Aryal S, Sartor M, Huang CM, Vecchio K, et al. Stimuli-responsive liposome fusion mediated by gold nanoparticles. ACS Nano. 2010;4(4):1935–42.PubMedGoogle Scholar
  59. 59.
    Wang HJ, Zhao PQ, Liang XF, Gong XQ, Song T, Niu RF, et al. Folate-PEG coated cationic modified chitosan - Cholesterol liposomes for tumor-targeted drug delivery. Biomaterials. 2010;31(14):4129–38.PubMedGoogle Scholar
  60. 60.
    Mevel M, Kamaly N, Carmona S, Oliver MH, Jorgensen MR, Crowther C, et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release. 2010;143(2):222–32.PubMedGoogle Scholar
  61. 61.
    Barua S, Rege K. The influence of mediators of intracellular trafficking on transgene expression efficacy of polymer-plasmid DNA complexes. Biomaterials. 2010;31(22):5894–902.PubMedGoogle Scholar
  62. 62.
    Contreras J, Xie J, Chen YJ, Pei H, Zhang G, Fraser CL, et al. Intracellular uptake and trafficking of difluoroboron dibenzoylmethane-polylactide nanoparticles in HeLa cells. ACS Nano. 2010;4(5):2735–47.PubMedGoogle Scholar
  63. 63.
    Ravindran J, Nair HB, Sung BY, Prasad S, Tekmal RR, Aggarwal BB. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem Pharmacol. 2010;79(11):1640–7.PubMedGoogle Scholar
  64. 64.
    Michel CC, Curry FE. Microvascular permeability. Physiol Rev. 1999;79(3):703–61.PubMedGoogle Scholar
  65. 65.
    Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev. 1993;73(1):1–78.PubMedGoogle Scholar
  66. 66.
    Clark RA, Folkvord JM, Hart CE, Murray MJ, McPherson JM. Platelet isoforms of platelet-derived growth factor stimulate fibroblasts to contract collagen matrices. J Clin Invest. 1989;84(3):1036–40.PubMedGoogle Scholar
  67. 67.
    Gullberg D, Tingstrom A, Thuresson AC, Olsson L, Terracio L, Borg TK, et al. Beta 1 integrin-mediated collagen gel contraction is stimulated by PDGF. Exp Cell Res. 1990;186(2):264–72.PubMedGoogle Scholar
  68. 68.
    Montesano R, Orci L. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci USA. 1988;85(13):4894–7.PubMedGoogle Scholar
  69. 69.
    Milosevic A, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol. 2004;14(3):249–58.PubMedGoogle Scholar
  70. 70.
    Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis. 2009;26(1):19–34.PubMedGoogle Scholar
  71. 71.
    Rofstad EK, Ruud EBM, Mathiesen B, Galappathi K. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin Cancer Res. 2010;16(3):936–45.PubMedGoogle Scholar
  72. 72.
    Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW, Madara K, et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 1993;53(10 Suppl):2204–7.PubMedGoogle Scholar
  73. 73.
    Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565–70.PubMedGoogle Scholar
  74. 74.
    Aukland K. Interstitial fluid balance in experimental animals and man. In: Staub NC, Hogg JC, Hargens AR, editors. Advances in Microcirculation, Vol 13 Interstitial-Lymphatic Liquid and Solute Movement; Satellite Symposium, Victoria, British Columbia, Canada, July 20–24, 1986 X + 290p S Karger Ag: Basel, Switzerland; New York, New York, USA Illus:110–123; 1987.Google Scholar
  75. 75.
    Hofmann M, McCormack E, Mujic M, Rossberg M, Bernd A, Bereiter-Hahn J, et al. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia. 2009;11(8):812–22.PubMedGoogle Scholar
  76. 76.
    Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991;51(24):6691–4.PubMedGoogle Scholar
  77. 77.
    Gutmann R, Leunig M, Feyh J, Goetz AE, Messmer K, Kastenbauer E, et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 1992;52(7):1993–5.PubMedGoogle Scholar
  78. 78.
    Nathanson SD, Nelson L. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann Surg Oncol. 1994;1(4):333–8.PubMedGoogle Scholar
  79. 79.
    Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62(19):5476–84.PubMedGoogle Scholar
  80. 80.
    Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, Manchul L, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor - oxygen measurements. Cancer Res. 2001;61(17):6400–5.PubMedGoogle Scholar
  81. 81.
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.PubMedGoogle Scholar
  82. 82.
    Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000;60(16):4324–7.PubMedGoogle Scholar
  83. 83.
    Klosowska-Wardega A, Hasumi Y, Burmakin M, Ahgren A, Stuhr L, Moen I, et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PLoS One. 2009;4(12):e8149.PubMedGoogle Scholar
  84. 84.
    Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464–78.PubMedGoogle Scholar
  85. 85.
    Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–39.PubMedGoogle Scholar
  86. 86.
    Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res. 2003;9(10 Pt 1):3779–87.PubMedGoogle Scholar
  87. 87.
    Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 2001;80:1–38.PubMedGoogle Scholar
  88. 88.
    Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200(4):500–3.PubMedGoogle Scholar
  89. 89.
    Rofstad EK, Gaustad JV, Brurberg KG, Mathiesen B, Galappathi K, Simonsen TG. Radiocurability is associated with interstitial fluid pressure in human tumor xenografts. Neoplasia. 2009;11(11):1243–51.PubMedGoogle Scholar
  90. 90.
    Rofstad EK, Tunheim SH, Mathiesen B, Graff BA, Halsør EF, Nilsen K, et al. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res. 2002;62(3):661–4.PubMedGoogle Scholar
  91. 91.
    Hofmann M, Guschel M, Bernd A, Bereiter-Hahn J, Kaufmann R, Tandi C, et al. Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia. 2006;8(2):89–95.PubMedGoogle Scholar
  92. 92.
    Hofmann M, Schultz M, Bernd A, Bereiter-Hahn J, Kaufmann R, Kippenberger S. Long-term lowering of tumour interstitial fluid pressure reduces Ki-67 expression. J Biomech. 2007;40(10):2324–9.PubMedGoogle Scholar
  93. 93.
    Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 1992;52(18):5110–4.PubMedGoogle Scholar
  94. 94.
    Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1):58–65.PubMedGoogle Scholar
  95. 95.
    Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039–51.PubMedGoogle Scholar
  96. 96.
    Cho YW, Park SA, Han TH, Son DH, Park JS, Oh SJ, et al. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials. 2007;28(6):1236–47.PubMedGoogle Scholar
  97. 97.
    Choi KY, Min KH, Na JH, Choi K, Kim K, Park JH, et al. Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. J Mater Chem. 2009;19(24):4102–7.Google Scholar
  98. 98.
    Park K, Kim J-H, Nam YS, Lee S, Nam HY, Kim K, et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release. 2007;122(3):305–14.PubMedGoogle Scholar
  99. 99.
    ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;5(6):1973–80.Google Scholar
  100. 100.
    Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009;6(4):1041–51.PubMedGoogle Scholar
  101. 101.
    Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong KL, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732–40.PubMedGoogle Scholar
  102. 102.
    Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA. 2007;104(39):15549–54.PubMedGoogle Scholar
  103. 103.
    Zhang X, Koh CG, Yu B, Liu S, Piao L, Marcucci G, et al. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model. Pharm Res. 2009;26(6):1516–24.PubMedGoogle Scholar
  104. 104.
    Nomura T, Koreeda N, Yamashita F, Takakura Y, Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res. 1998;15(1):128–32.PubMedGoogle Scholar
  105. 105.
    Reddy LH, Sharma RK, Murthy RSR. Enhanced tumour uptake of doxorubicin loaded Poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton’s lymphoma tlimour. J Drug Target. 2004;12(7):443–51.PubMedGoogle Scholar
  106. 106.
    Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem. 2005;16(1):122–30.PubMedGoogle Scholar
  107. 107.
    Goodman TT, Chen JY, Matveev K, Pun SH. Spatio-temporal modeling of nanoparticle delivery to multicellular tumor spheroids. Biotechnol Bioeng. 2008;101(2):388–99.PubMedGoogle Scholar
  108. 108.
    Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm. 2010;7(4):1195–208.PubMedGoogle Scholar
  109. 109.
    Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4):487–95.PubMedGoogle Scholar
  110. 110.
    Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93–102.PubMedGoogle Scholar
  111. 111.
    Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab. 2010;11(2):129–41.PubMedGoogle Scholar
  112. 112.
    Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002;62(23):6831–6.PubMedGoogle Scholar
  113. 113.
    Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer. 2000;82(9):1513–8.PubMedGoogle Scholar
  114. 114.
    Kim B, Han G, Toley BJ, Kim CK, Rotello VM, Forbes NS. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol. 2010;5(6):465–72.PubMedGoogle Scholar
  115. 115.
    Stylianopoulos T, Poh MZ, Insin N, Bawendi MG, Fukumura D, Munn LL, et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J. 2010;99(5):1342–9.PubMedGoogle Scholar
  116. 116.
    Lieleg O, Baumgärtel RM, Bausch AR. Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophys J. 2009;97(6):1569–77.PubMedGoogle Scholar
  117. 117.
    Mamot C, Drummond DC, Noble CO, Kallab V, Guo ZX, Hong KL, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65(24):11631–8.PubMedGoogle Scholar
  118. 118.
    Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res. 2003;9(17):6551–9.PubMedGoogle Scholar
  119. 119.
    Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 2006;103(16):6315–20.PubMedGoogle Scholar
  120. 120.
    Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52(19):5144–53.PubMedGoogle Scholar
  121. 121.
    Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids. Cancer Res. 2003;63(6):1288–96.PubMedGoogle Scholar
  122. 122.
    Lo CM, Wang HB, Dembo M, Wang YL. Cell movement is guided by the rigidity of the substrate. Biophys J. 2000;79(1):144–52.PubMedGoogle Scholar
  123. 123.
    Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res. 2009;26(2):395–403.PubMedGoogle Scholar
  124. 124.
    Zhang Y, So MK, Rao JH. Protease-modulated cellular uptake of quantum dots. Nano Lett. 2006;6(9):1988–92.PubMedGoogle Scholar
  125. 125.
    Eikenes L, Tari M, Tufto I, Bruland OS, Davies CD. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx (TM)) in human osteosarcoma xenografts. Br J Cancer. 2005;93(1):81–8.PubMedGoogle Scholar
  126. 126.
    Kerbel RS, St Croix B, Florenes VA, Rak J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell. 1996;9(4):257–64.PubMedGoogle Scholar
  127. 127.
    St Croix B, Man S, Kerbel RS. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett. 1998;131(1):35–44.PubMedGoogle Scholar
  128. 128.
    Baumgartner G, Gomar-Höss C, Sakr L, Ulsperger E, Wogritsch C. The impact of extracellular matrix on the chemoresistance of solid tumors - experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 1998;131(1):85–99.PubMedGoogle Scholar
  129. 129.
    Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003;9(6):796–800.PubMedGoogle Scholar
  130. 130.
    Novak K. Measuring the matrix. Nat Rev Cancer. 2003;3:394.Google Scholar
  131. 131.
    Kuhn SJ, Finch SK, Hallahan DE, Giorgio TD. Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. Nano Lett. 2006;6(2):306–12.PubMedGoogle Scholar
  132. 132.
    Goodman TT, Olive PL, Pun SH. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int J Nanomedicine. 2007;2(2):265–74.PubMedGoogle Scholar
  133. 133.
    Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer. 2008;8(4):309–16.PubMedGoogle Scholar
  134. 134.
    Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.PubMedGoogle Scholar
  135. 135.
    Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731–6.PubMedGoogle Scholar
  136. 136.
    Altmann KH, Wartmann M, O’Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000;1470(3):M79–91.PubMedGoogle Scholar
  137. 137.
    Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325–33.PubMedGoogle Scholar
  138. 138.
    Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61(7):2929–34.PubMedGoogle Scholar
  139. 139.
    Lee I, Boucher Y, Jain RK. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res. 1992;52(11):3237–40.PubMedGoogle Scholar
  140. 140.
    Kristjansen PEG, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res. 1993;53(20):4764–6.PubMedGoogle Scholar
  141. 141.
    Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer. 1996;74(4):533–6.PubMedGoogle Scholar
  142. 142.
    Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002;110(4):475–82.PubMedGoogle Scholar
  143. 143.
    Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18(11):1185–90.PubMedGoogle Scholar
  144. 144.
    Rubin K, Sjoquist M, Gustafsson AM, Isaksson B, Salvessen G, Reed RK. Lowering of tumoral interstitial fluid pressure by prostaglandin E-1 is paralleled by an increased uptake of Cr-51-EDTA. Int J Cancer. 2000;86(5):636–43.PubMedGoogle Scholar
  145. 145.
    Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 2003;17(12):1756–8.PubMedGoogle Scholar
  146. 146.
    Emerich DF, Dean RL, Snodgrass P, Lafreniere D, Agostino M, Wiens T, et al. Bradykinin modulation of tumor vasculature: II. Activation of nitric oxide and phospholipase A(2)/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther. 2001;296(2):632–41.PubMedGoogle Scholar
  147. 147.
    Lammerts E, Roswall P, Sundberg C, Gotwals PJ, Koteliansky VE, Reed RK, et al. Interference with TGF-beta 1 and -beta 3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int J Cancer. 2002;102(5):453–62.PubMedGoogle Scholar
  148. 148.
    Brekken C, Davies CD. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett. 1998;131(1):65–70.PubMedGoogle Scholar
  149. 149.
    Jang SH, Wientjes MG, Au JLS. Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs. 2001;19(2):113–23.PubMedGoogle Scholar
  150. 150.
    Zheng JH, Chen CT, Au JLS, Wientjes MG. Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci. 2001;3(2):E15.PubMedGoogle Scholar
  151. 151.
    Jang SH, Wientjes MG, Au JLS. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther. 2001;296(3):1035–42.PubMedGoogle Scholar
  152. 152.
    Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JLS. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2008;327(3):673–82.PubMedGoogle Scholar
  153. 153.
    Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 1999;59(15):3776–82.PubMedGoogle Scholar
  154. 154.
    Kuhn SJ, Hallahan DE, Giorgio TD. Characterization of superparamagnetic nanoparticle interactions with extracellular matrix in an in vitro system. Ann Biomed Eng. 2006;34(1):51–8.PubMedGoogle Scholar
  155. 155.
    Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia. 2004;20(7):781–802.PubMedGoogle Scholar
  156. 156.
    Goldberg SN, Saldinger PF, Gazelle GS, Huertas JC, Stuart KE, Jacobs T, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology. 2001;220(2):420–7.PubMedGoogle Scholar
  157. 157.
    Goldberg SN, Girnan GD, Lukyanov AN, Ahmed M, Monsky WL, Gazelle GS, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology. 2002;222(3):797–804.PubMedGoogle Scholar
  158. 158.
    Monsky WL, Kruskal JB, Lukyanov AN, Girnun GD, Ahmed M, Gazelle GS, et al. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology. 2002;224(3):823–9.PubMedGoogle Scholar
  159. 159.
    Zhang A, Mi X, Yang G, Xu LX. Numerical study of thermally targeted liposomal drug delivery in tumor. J Heat Transfer. 2009;131:043209.Google Scholar
  160. 160.
    Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691–744.PubMedGoogle Scholar
  161. 161.
    Lee H, Hoang B, Fonge H, Reilly R, Allen C. In vitro distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res. 2010;27(11):2343–55.PubMedGoogle Scholar
  162. 162.
    Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2007;2(4):249–55.PubMedGoogle Scholar
  163. 163.
    Fox ME, Szoka FC, Fréchet JMJ. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res. 2009;42(8):1141–51.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Industrial and Physical Pharmacy, College of PharmacyPurdue UniversityWest LafayetteUSA
  2. 2.Department of Industrial and Physical Pharmacy, College of Pharmacy, and Weldon School of Biomedical EngineeringPurdue UniversityWest LafayetteUSA

Personalised recommendations